Senores Pharmaceuticals Schedules Q2 and H1 FY27 Earnings Call
Senores Pharmaceuticals Ltd 路 Intimation 路 29 Oct 2026, 5:00 pm
Senores Pharmaceuticals Schedules Q2 and H1 FY27 Earnings Call Senores Pharmaceuticals Limited will host its Q2 and H1 FY27 post-results earnings conference call on 29th Oct'26 at 17:00 IST, following the release of its un-audited standalone and consolidated financial results for the period ended 30th Sep'26. Organized by DAM Capital Advisors, the call will feature Managing Director Swapnil Shah, Chairman Sanjay Majmudar, and Whole Time Director & CFO Deval Shah to discuss financial performance. Universal dial-in numbers include +91 22 6280 1384 and +91 22 7115 8285, alongside international toll-free options.
Original exchange filing (PDF)
More announcements from Senores Pharmaceuticals Ltd
- We are pleased to announce that the manufacturing facility of our Subsidiary Company., Ratnatris Pharmaceuticals Private Limited has been awarded with the prestigious PIC/S GMP certification .... 路 18 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding transcript of earnings conference call held on October 29, 2026 路 05 Nov 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding audio recording of earnings conference call for quarter ended September 30, 2026 路 30 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds raised through preferential issue of convertible .... 路 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding submission of statement of deviation or variation in utilisation of funds of public issue for quarter ended on September 30, 2026 路 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Monitoring Agency report for the quarter ended September 30, 2026 路 29 Oct 2026
- We enclose herewith the Investor Presentation for Q2 & H1FY27 路 29 Oct 2026
- Senores Pharmaceuticals Limited has informed the exchange regarding Appointment of joint Statutory Auditor of the Company 路 29 Oct 2026
